Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001378078 | SCV001575565 | pathogenic | Ornithine carbamoyltransferase deficiency | 2023-08-17 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This sequence change replaces glycine, which is neutral and non-polar, with glutamic acid, which is acidic and polar, at codon 269 of the OTC protein (p.Gly269Glu). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with ornithine transcarbamylase deficiency (PMID: 7474905, 24449986; Invitae). ClinVar contains an entry for this variant (Variation ID: 97334). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt OTC protein function. This variant disrupts the p.Gly269 amino acid residue in OTC. Other variant(s) that disrupt this residue have been observed in individuals with OTC-related conditions (PMID: 28266016, 30285816), which suggests that this may be a clinically significant amino acid residue. |
Gen |
RCV000083581 | SCV000115667 | pathogenic | not provided | no assertion criteria provided | not provided | Converted during submission to Pathogenic. |